Ionis Pharmaceuticals (IONS) Non-Current Debt (2016 - 2024)
Historic Non-Current Debt for Ionis Pharmaceuticals (IONS) over the last 16 years, with Q4 2024 value amounting to $51.9 million.
- Ionis Pharmaceuticals' Non-Current Debt rose 2411.32% to $51.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $51.9 million, marking a year-over-year increase of 2411.32%. This contributed to the annual value of $51.9 million for FY2024, which is 2411.32% up from last year.
- Ionis Pharmaceuticals' Non-Current Debt amounted to $51.9 million in Q4 2024, which was up 2411.32% from $41.8 million recorded in Q4 2023.
- Over the past 5 years, Ionis Pharmaceuticals' Non-Current Debt peaked at $60.0 million during Q2 2021, and registered a low of $8.8 million during Q1 2023.
- Its 5-year average for Non-Current Debt is $51.7 million, with a median of $59.7 million in 2021.
- The largest annual percentage gain for Ionis Pharmaceuticals' Non-Current Debt in the last 5 years was 16191.7% (2023), contrasted with its biggest fall of 8518.21% (2023).
- Quarter analysis of 5 years shows Ionis Pharmaceuticals' Non-Current Debt stood at $60.0 million in 2020, then dropped by 0.45% to $59.7 million in 2021, then plummeted by 73.25% to $16.0 million in 2022, then surged by 161.92% to $41.8 million in 2023, then increased by 24.11% to $51.9 million in 2024.
- Its Non-Current Debt was $51.9 million in Q4 2024, compared to $41.8 million in Q4 2023 and $8.8 million in Q1 2023.